Ulsan College

Journal of Craniofacial Surgery Study Proves Planatome Blades Reduce Tissue Damage and Improve Diabetic Wound Healing from Surgical Incisions

Retrieved on: 
星期四, 四月 18, 2024
Microsurgery, University, Rat, MMM, Inflammation, Hope, Risk, Craniofacial surgery, Diabetes, Ulsan College, Craniofacial, Surgeon, Doctor of Philosophy, Tearing, Research, Foot, Asan Medical Center, Patient, Immunodeficiency, Nano, MBA, Wound healing, Journal, Plastic, Dentistry

The study highlights the superior performance of Planatome blades in surgical procedures, particularly noting their ability to reduce incisional tissue damage, which reduced inflammation in diabetic rats.

Key Points: 
  • The study highlights the superior performance of Planatome blades in surgical procedures, particularly noting their ability to reduce incisional tissue damage, which reduced inflammation in diabetic rats.
  • The study found that using ultra-smooth blade technology significantly mitigated tissue injury, which, in turn, lessened inflammation and hasten wound healing.
  • Scar measurements proved a statistically significant reduction in scar width and scar tissue formation along the incisions made with Planatome blades.
  • The analysis demonstrated that incisions made using nano-polished Planatome blades resulted in more even, cleaner margins and less damage to surrounding tissue.

OliX Pharmaceuticals Publishes Preclinical Research Demonstrating OLX104C’s Potential as an Effective Treatment for Hair Loss

Retrieved on: 
星期二, 十一月 22, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, University of Ulsan College of Medicine, Hair loss, KOSDAQ, Disorder, RNA interference, Therapy, University, Ulsan College, Asan Medical Center, AR, Treatment, Pharmaceutical industry, Molecular Pharmaceutics

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced the publication of preclinical research on the androgenetic alopecia (hair loss) treatment program, OLX104C, in Molecular Pharmaceutics .

Key Points: 
  • OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced the publication of preclinical research on the androgenetic alopecia (hair loss) treatment program, OLX104C, in Molecular Pharmaceutics .
  • The Company is developing the treatment for androgenetic alopecia based on cell-penetrating asymmetric siRNA (cp-asiRNA) platform technology.
  • The research team demonstrated the efficacy of AR reduction, hair loss inhibition, and long duration of action in primary cultured human follicle dermal papilla cells (HFDPC) and rodent models of hair loss.
  • OliX Pharmaceuticals is a clinical-stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating the expression of disease-causing genes based on its own proprietary RNAi technology.

Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

Retrieved on: 
星期四, 十一月 10, 2022
AstraZeneca, Private Securities Litigation Reform Act, IV, IND, Nivolumab, Vaccine, U.S. Securities and Exchange Commission, ChAdOx1, MVA, Tumor microenvironment, Research, AASLD, HPV, G&A, Șaeș, SEC, Annual report, Degenerative disease, University, Vaccitech, Company, Vaccination, Cancer, Asian Liver Center, CHB, Clinical trial, OUI, Patient, Immune system, Autoimmunity, Ulsan College, Drug discovery, Security (finance), Insurance, COVID-19, Pharmaceutical industry, Food delivery, HBsAg, Gastroenterology, Cell

An Investigational New Drug (IND) application submission is expected during the first half of 2023 for HPV related cancer.

Key Points: 
  • An Investigational New Drug (IND) application submission is expected during the first half of 2023 for HPV related cancer.
  • On September 20, 2022, we announced the promotion of Gemma Brown to Chief Financial Officer.
  • Vaccitech is entitled to receive a share of all milestone and royalty income received by OUI from AstraZeneca related to Vaxzevria.
  • The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.

Vaccitech Provides Update on Ongoing VTP-300 Phase 1b/2a Trial Showing Sustained Reductions of HBsAg in Patients with Chronic Hepatitis B

Retrieved on: 
星期一, 十一月 7, 2022
University of Ulsan College of Medicine, Liver disease, Patient, Immune tolerance, Ulsan College, IB Group 2 subjects, Liver, Nivolumab, GLOBE, Asian Liver Center, Modified vaccinia Ankara, Safety, Department, Poster, Group 3, Group 1, University, AASLD, Group 2, HBV, MVA, Vaccine, NASDAQ, Hepatitis, Infection, Disease, Antigen, Degenerative disease, American Association, Association, Cancer, Group 4, OXFORD, Pharmaceutical industry, Vaccitech, HBsAg

OXFORD, United Kingdom, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapies and vaccines for the treatment and prevention of infectious diseases, cancer, and autoimmune diseases, today announced an update to the interim analysis of safety and efficacy data from its HBV002 trial (NCT04778904). The data will be presented as a poster at the 2022 American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® by Dr. Young-Suk Lim, Professor of the Department of Gastroenterology and the Liver Center, Asian Medical Center, University of Ulsan College of Medicine, Korea.

Key Points: 
  • VTP-300 induced sustained reductions of hepatitis B surface antigen in people with chronic hepatitis B during ongoing, fully enrolled Phase 1b/2a trial.
  • Vaccitechs updated interim analysis includes data from the fully-enrolled trial of 55 patients with chronic hepatitis B (HBV) with at least three months of follow-up.
  • It shows that VTP-300 induced meaningful, sustained reductions of HBV surface antigen (HBsAg) in people with chronic HBV.
  • Enrollment in the HBV002 trial is complete, with a final update expected early in the second quarter of 2023.

AC Immune Announces Upcoming Presentations at the Alzheimer’s Association International Conference

Retrieved on: 
星期五, 七月 22, 2022
CH, Genentech, University, Asan Medical Center, University of Antioquia, Immunity, Doctor of Philosophy, Neurodegeneration, NO, JP, RU, Hoffmann-La Roche, Parallel, Safety, University of Ulsan College of Medicine, GB, Eli Lilly and Company, AD, Teaching hospital, Company, MD, Biomarker, Precision medicine, Janssen Pharmaceuticals, Ulsan College, AC, Mutation, API, AU, Pharmaceutical industry, EU

API ADAD Colombia Trial initial findings: a randomized, double-blind, placebo-controlled, parallel- group study in cognitively unimpaired PSEN1 E280A mutation carriers evaluating efficacy and safety of crenezumab

Key Points: 
  • API ADAD Colombia Trial initial findings: a randomized, double-blind, placebo-controlled, parallel- group study in cognitively unimpaired PSEN1 E280A mutation carriers evaluating efficacy and safety of crenezumab
    Margarita Giraldo-Chica (Grupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellin, Colombia)
    Selecting appropriate meaningful change thresholds for trials of early (prodromal-to-mild) AD: A caregiver-rated, anchor-based analysis based on the Tauriel Study
    Minyoung Oh, MD, PhD, (Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea)
    Initial clinical scans using [18F]ACI-12589, a novel -synuclein PET-tracer
    Prof. Ruben Smith (Skne University Hospital, Lund, Sweden)
    Optimized ACI-24, an amyloid beta (Abeta) vaccine that safely drives immunity to oligomers and pyroglutamate Abeta, key pathological species of Alzheimers disease (AD)
    Biomarker-based development for optimized ACI-24, a novel candidate vaccine for the treatment and prevention of Alzheimers disease
    AC Immune SAis a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimers disease, Parkinsons disease, and NeuroOrphan indications driven by misfolded proteins.
  • The Companys two clinically validated technology platforms, SupraAntigen and Morphomer, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, six of which are currently in clinical trials.AC Immunehas a strong track record of securing strategic partnerships with leading global pharmaceutical companies includingGenentech, a member of the Roche Group, Eli Lilly and Company, andJanssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >$3billionin potential milestone payments.
  • SupraAntigen is a registered trademark ofAC Immune SAin the following territories: AU, EU, CH, GB, JP and RU.
  • Morphomer is a registered trademark ofAC Immune SAin CN, CH, GB, JP, and NO.

Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program

Retrieved on: 
星期六, 六月 25, 2022
Abstract, Patient, Ulsan College, Research, University of Ulsan College of Medicine, GLOBE, COVID-19, Blood, Company, Immune system, HIV, ILC, Serum, Hepatitis B, Monoclonality, Annual general meeting, AES, Infection, SAN, Nivolumab, Half-life, Forward-looking statement, Gilead Sciences, European Association of Urology, Poster, HBV, Hepatocyte, Therapeutic index, Drug development, Technology, Private Securities Litigation Reform Act, Vir, Phase II, Hepatitis B virus, Institute, EASL, U.S. Securities and Exchange Commission, PD-1, Association, Plasma, Mortality, Risk, Clinical trial, HDV, Safety, Disease, Asan Medical Center, HBeAg, European Association for the Study of the Liver, Pharmaceutical industry, Vaccine, Copper, Part, Liver, HBsAg

SAN FRANCISCO, June 25, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from its robust hepatitis B virus (HBV) clinical trial program, including results from an ongoing Phase 2 clinical trial of VIR-2218, results from an ongoing Phase 1 clinical trial of VIR-3434 and preclinical data evaluating both investigational compounds as monotherapy and in combination. Data were presented in one oral and two poster presentations at the International Liver Congress™ (ILC) 2022, the Annual Meeting of the European Association for the Study of the Liver (EASL).

Key Points: 
  • SAN FRANCISCO, June 25, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from its robust hepatitis B virus (HBV) clinical trial program, including results from an ongoing Phase 2 clinical trial of VIR-2218, results from an ongoing Phase 1 clinical trial of VIR-3434 and preclinical data evaluating both investigational compounds as monotherapy and in combination.
  • These data, alongside the anticipated initiation of Part B of the MARCH trial by the end of June, are important milestones in our broad HBV portfolio for which we expect multiple data readouts throughout 2022 and 2023.
  • Chronic hepatitis B virus (HBV) infection remains an urgent global public health challenge associated with significant morbidity and mortality.
  • Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and hepatitis D viruses, influenza A and human immunodeficiency virus.

Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at the International Liver Congress™ 2022

Retrieved on: 
星期三, 六月 8, 2022
Hepatocyte, EDT, Hepatitis B, Blood, HBV, Technology, COVID-19, Immune system, European Association for the Study of the Liver, Asan Medical Center, U.S. Securities and Exchange Commission, ILC, EASL, Forward-looking statement, Half-life, Drug development, Hepatitis B virus, BST, HIV, Association, Institute, Sirna, Cell, Abstract, RNA interference, RNA, University, University of Ulsan College of Medicine, Patient, Disease, Biotechnology, Infection, Poster, Department, Private Securities Litigation Reform Act, Research, Ulsan College, Annual general meeting, Therapeutic index, 2021 Essex County Council election, GLOBE, Mortality, Risk, SAN, Clinical trial, Safety, Pharmaceutical industry, Vaccine, Liver

The second poster presentation will showcase preclinical in vivo data demonstrating that the combination of VIR-2218 plus VIR-3434 resulted in greater surface antigen reductions than monotherapy with either therapy.

Key Points: 
  • The second poster presentation will showcase preclinical in vivo data demonstrating that the combination of VIR-2218 plus VIR-3434 resulted in greater surface antigen reductions than monotherapy with either therapy.
  • Approximately 300 million people around the world are living with HBV and about 900,000 die from HBV-associated complications each year.
  • Vir Biotechnology is working to achieve a functional cure for the millions of people with hepatitis B around the world through its broad and differentiated portfolio.
  • The Companys current development pipeline consists of product candidates targeting COVID-19, hepatitis B and hepatitis D viruses, influenza A and human immunodeficiency virus.